2021 Q1 Form 10-Q Financial Statement
#000156459021026307 Filed on May 11, 2021
Income Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| Revenue | $1.222M | $935.0K |
| YoY Change | 30.7% | |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $4.010M | $3.290M |
| YoY Change | 21.88% | 97.01% |
| % of Gross Profit | ||
| Research & Development | $13.77M | $10.68M |
| YoY Change | 28.91% | 35.74% |
| % of Gross Profit | ||
| Depreciation & Amortization | $280.0K | $200.0K |
| YoY Change | 40.0% | -39.39% |
| % of Gross Profit | ||
| Operating Expenses | $17.78M | $13.97M |
| YoY Change | 27.28% | 46.4% |
| Operating Profit | -$16.56M | -$13.04M |
| YoY Change | 27.03% | 36.6% |
| Interest Expense | ||
| YoY Change | ||
| % of Operating Profit | ||
| Other Income/Expense, Net | $47.00K | $135.0K |
| YoY Change | -65.19% | -62.08% |
| Pretax Income | -$16.51M | -$12.90M |
| YoY Change | 28.0% | 40.42% |
| Income Tax | $0.00 | $237.0K |
| % Of Pretax Income | ||
| Net Earnings | -$16.51M | -$13.14M |
| YoY Change | 25.69% | 43.0% |
| Net Earnings / Revenue | -1351.39% | -1405.24% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$664.7K | -$564.7K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 24.87M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $98.40M | $138.2M |
| YoY Change | -28.8% | 123.62% |
| Cash & Equivalents | $24.72M | $91.53M |
| Short-Term Investments | $73.70M | $46.70M |
| Other Short-Term Assets | $4.200M | $3.700M |
| YoY Change | 13.51% | 146.67% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $5.000M | |
| Other Receivables | $0.00 | |
| Total Short-Term Assets | $102.6M | $146.9M |
| YoY Change | -30.15% | 132.43% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $2.900M | $3.606M |
| YoY Change | -19.58% | -14.14% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $400.0K | $389.0K |
| YoY Change | 2.83% | -2.75% |
| Total Long-Term Assets | $3.300M | $3.995M |
| YoY Change | -17.4% | -15.0% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $102.6M | $146.9M |
| Total Long-Term Assets | $3.300M | $3.995M |
| Total Assets | $105.9M | $150.9M |
| YoY Change | -29.82% | 122.22% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $3.100M | $3.409M |
| YoY Change | -9.06% | 162.23% |
| Accrued Expenses | $4.500M | $3.832M |
| YoY Change | 17.43% | 125.41% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $11.10M | $13.44M |
| YoY Change | -17.42% | 284.06% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $3.100M | $5.500M |
| YoY Change | -43.64% | 161.9% |
| Total Long-Term Liabilities | $3.100M | $5.500M |
| YoY Change | -43.64% | 161.9% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $11.10M | $13.44M |
| Total Long-Term Liabilities | $3.100M | $5.500M |
| Total Liabilities | $14.28M | $19.00M |
| YoY Change | -24.83% | 239.29% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$231.4M | -$175.1M |
| YoY Change | 32.14% | |
| Common Stock | $323.2M | $307.0M |
| YoY Change | 5.27% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $91.64M | $131.9M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $105.9M | $150.9M |
| YoY Change | -29.8% | 122.22% |
Cashflow Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$16.51M | -$13.14M |
| YoY Change | 25.69% | 43.0% |
| Depreciation, Depletion And Amortization | $280.0K | $200.0K |
| YoY Change | 40.0% | -39.39% |
| Cash From Operating Activities | -$13.91M | -$8.745M |
| YoY Change | 59.06% | 1.29% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $227.0K | $98.00K |
| YoY Change | 131.63% | -76.61% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $12.64M | -$46.88M |
| YoY Change | -126.96% | |
| Cash From Investing Activities | $12.41M | -$46.98M |
| YoY Change | -126.42% | 11112.65% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $1.180M | $69.84M |
| YoY Change | -98.31% | |
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 1.301M | 69.87M |
| YoY Change | -98.14% | 896.32% |
| NET CHANGE | ||
| Cash From Operating Activities | -13.91M | -8.745M |
| Cash From Investing Activities | 12.41M | -46.98M |
| Cash From Financing Activities | 1.301M | 69.87M |
| Net Change In Cash | -198.0K | 14.15M |
| YoY Change | -101.4% | -793.43% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$13.91M | -$8.745M |
| Capital Expenditures | $227.0K | $98.00K |
| Free Cash Flow | -$14.14M | -$8.843M |
| YoY Change | 59.87% | -2.32% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
13771000 | |
| CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
10683000 | |
| CY2021Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | |
| CY2021Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-189000 | |
| CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-177000 | |
| CY2021Q1 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
73686000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
38000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16514000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-50000 | |
| CY2021Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-16526000 | |
| CY2021Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.66 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
24844946 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
73121000 | |
| CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2021Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2021Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2021Q1 | us-gaap |
Liabilities
Liabilities
|
14283000 | |
| CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
14790000 | |
| CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | |
| CY2021Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
323184000 | |
| CY2020Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
319196000 | |
| CY2021Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-231356000 | |
| CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-214842000 | |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
91641000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
104179000 | |
| CY2021Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
105924000 | |
| CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
118969000 | |
| CY2021Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
1222000 | |
| CY2020Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
935000 | |
| CY2020Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
13972000 | |
| CY2021Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4012000 | |
| CY2020Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3289000 | |
| CY2021Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
17783000 | |
| CY2021Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-16561000 | |
| CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13037000 | |
| CY2020Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
135000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13139000 | |
| CY2021Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
47000 | |
| CY2021Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-16514000 | |
| CY2020Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-12902000 | |
| CY2020Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
237000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
112000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
562000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
204000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-217000 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-13152000 | |
| CY2021Q1 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
-218000 | |
| CY2020Q1 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
4000 | |
| CY2021Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
280000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2687000 | |
| CY2021Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-38000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
0 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
5010000 | |
| CY2020Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.56 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
23266063 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
1180000 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
121000 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
2687000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
69842000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
30000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
131929000 | |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-16514000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
362000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
2421000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-841000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
5065000 | |
| CY2021Q1 | rapt |
Increase Decrease In Deferred Rent Current And Noncurrent
IncreaseDecreaseInDeferredRentCurrentAndNoncurrent
|
-28000 | |
| CY2020Q1 | rapt |
Increase Decrease In Deferred Rent Current And Noncurrent
IncreaseDecreaseInDeferredRentCurrentAndNoncurrent
|
-7000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-13910000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-8745000 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
15734000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
46883000 | |
| CY2021Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
28372000 | |
| CY2020Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
0 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
227000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
12411000 | |
| CY2021Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1180000 | |
| CY2021Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
121000 | |
| CY2020Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
30000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1301000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
69872000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-198000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
14146000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
24918000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
77383000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
24720000 | |
| CY2021Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Organization </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of the Business </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RAPT Therapeutics, Inc. (“RAPT” or the “Company”) is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary drug discovery and development engine, the Company develops highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is located in South San Francisco, California.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Equity Financing</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2021, the Company sold 57,100 shares of common stock in “at the market” offerings pursuant to a Controlled Equity Offering<sup style="font-size:85%;line-height:120%;vertical-align:top">SM</sup> Sales Agreement with Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated (the “ATM Sales Agreement”), for net proceeds of $1.2 million after deducting underwriting discounts and commissions and other offering related costs. As of March 31, 2021, there was up to $94.5 million available for future issuance of shares of common stock under the ATM Sales Agreement.</p> | |
| CY2021Q1 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
14168000 | |
| CY2021Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
96245000 | |
| CY2021Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
19000 | |
| CY2021Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
17000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
136866000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
217000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
136649000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
82079000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
96247000 | |
| CY2021Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
10291000 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
10064000 | |
| CY2021Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
7362000 | |
| CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
7082000 | |
| CY2021Q1 | rapt |
Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
|
2060000 | |
| CY2020Q4 | rapt |
Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
|
1576000 | |
| CY2021Q1 | us-gaap |
Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
|
2167000 | |
| CY2020Q4 | us-gaap |
Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
|
2967000 | |
| CY2021Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
248000 | |
| CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
129000 | |
| CY2021Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
64000 | |
| CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
263000 | |
| CY2021Q1 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
5304096 | |
| CY2021Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2687000 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2088000 | |
| CY2021Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
18000000 | |
| CY2021Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
24844946 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
23317161 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
|
51098 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.66 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.56 | |
| CY2021Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2060385 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1611955 |
